ALY688-SR in Generally Healthy Overweight or Obese Adults

• Status: Terminated
• Trial end date: 2021-08-03
• Target enrollment: 0
• Participant gender: All

Summary

First in human study of ALY688-SR administered as a subcutaneous injection

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Allysta Pharmaceutical
• Collaborator: INC Research Australia Pty Ltd

Criteria

Inclusion Criteria:

• Body mass index 24 to 35 kg/m2 Body weight 60 to 120 kg,

Exclusion Criteria:

• Confirmed diabetes on treatment Inadequately managed hypertension Poorly controlled hypercholesterolemia